Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Gilead Sciences, Inc. (NASD: GILD), where a total volume of 43,947 contracts has been traded thus far today, a contract volume...
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) announced the
initiation of a Phase 2 clinical trial with the company's glucagon receptor
antagonist LGD-6972 for the treatment of type 2 diabetes mellitus. The
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) partner Retrophin,
Inc. (RTRX) reported positive top-line results from the Phase 2 DUET study of
sparsentan for the treatment of focal segmental glomerulosclerosis, a kidney
Analysts at CIBC upgraded Spectra Energy Corp. (NYSE: SE) from Sector Performer to Outperformer. Spectra Energy shares declined 1.10 percent to $40.55 in pre-market trading.
Deutsche Bank upgraded Ligand Pharmaceuticals Inc. ...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Ligand Pharmaceuticals (LGND):